Amir Najafi, Mohammad Amin Momeni-Moghaddam, Dr Davoud Salarbashi, Narges Amini Beidokhti, Marziye Rahmani, Milad Khorasani,
Volume 27, Issue 3 (7-2024)
Abstract
Introduction: Type 2 diabetes is a non-communicable disease that imposes a significant financial burden on the healthcare system each year. Numerous studies have demonstrated the involvement of inflammatory factors in the initiation and progression of this condition. The primary goal of this study is to compare the polymorphism of the interleukin 1 receptor antagonist gene among individuals with type 2 diabetes and those in the control group.
Methods: Following approval from the Ethics Committee of Gonabad University of Medical Sciences, blood samples were collected from 100 participants at Bohlool Hospital in Gonabad. These individuals were categorized into two groups: cases (individuals with type 2 diabetes) and controls (healthy individuals). DNA extraction was carried out using the salting out method. To examine the polymorphism, the specific segment was initially amplified through PCR with designated primers and then identified via gel electrophoresis. The data were analyzed using subjected to the Chi-square test at a significance level below 5%.
Results: Findings from the polymorphism analysis revealed a notable contrast in the genotype 2/1 (P = 0.001) and 2/2 (P = 0.004) within the case group when compared to the healthy participants. Specifically, individuals with genotype 2/1 exhibited a heightened risk of developing type 2 diabetes by up to 15 times.
Conclusions: Within the examined population, the polymorphism of the interleukin 1 receptor antagonist gene substantially influenced the predisposition to type 2 diabetes, amplifying the likelihood of developing this ailment. Individuals harboring allele 2 are at an increased susceptibility to type 2 diabetes.
Hosein Sarmadian, Nader Zarinfar, Masoud Bahrami, Mohammad Matin Arjmandzadegan, Dr Roham Sarmadian, Yasamin Zarinfar,
Volume 27, Issue 6 (1-2025)
Abstract
Introduction: The Symptoms of Omicron are still unknown. Primary data show that the Omicron symptoms are mainly related to the respiratory system, including runny nose, sore throat, headache, fatigue, and sneezing. Based on the need for more evidence about Omicron symptoms, this study was conducted to investigate the symptoms of this COVID serotype.
Methods: This descriptive-analytical cross-sectional study was performed for 6 months in Arak city on 160 definitively diagnosed patients with Omicron. For all patients who entered the study, the information evaluation checklist, including demographics and symptoms (24 symptoms), was completed. Disease diagnosis was done by PCR.
Results: The disease of 55% of people was mild, 35% moderate, and 10% severe. Fifty-one people (31.9%) mentioned a history of previous infection with COVID-19. Pulmonary involvement, the type of drug used, and anxiety at the time of infection were related to the severity of the disease (P < 0.05). The five most common symptoms of Omicron (%) were sore throat (86.3), cough (82.5), weakness and lethargy (76.3), headache (72.5) and dry mouth (62.5). There was also a relationship between old age with dry mouth and headache, underlying disease with sneezing, anxiety during illness with joint pain and chest pain, and smoking with abdominal pain (P < 0.05).
Conclusions: The most common symptoms included sore throat, cough, weakness and lethargy, headache, and musculoskeletal pain. However, reduced smell and taste, night sweats, fever, and joint pain, common in the previous serotypes, were among the less frequent symptoms of Omicron.
